noom glp 1 reviews before and after I Did the Whole Program. Here's How It Really Went Noom vs Calibrate: Which Fits

Four states dropped coverage in late 2025: California, New Hampshire, Pennsylvania , and South Carolina all eliminated Medicaid coverage of GLP-1s for obesity treatment reducing the national count from 16 states to 13

These may be manageable for some but concerning for others, particularly those with pre-existing health conditions

10.1186/S12933-021-01400-9/FIGURES/1 19 GiuglianoD.ScappaticcioL.LongoM.CarusoP.MaiorinoM

[13] [14] UK SmPCs for licensed GLP-1 receptor agonists do not list medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) as formal contraindications, but advise vigilance for symptoms such as a neck lump, hoarseness, or difficulty swallowing

At the same time, individual mood changes during treatment are real and worth taking seriously